Update on pharmacogenetics in cancer chemotherapy
- 1 March 2002
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 38 (5) , 639-644
- https://doi.org/10.1016/s0959-8049(01)00434-8
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activityClinical Pharmacology & Therapeutics, 2001
- Preponderance of Thiopurine S-Methyltransferase Deficiency and Heterozygosity Among Patients Intolerant to Mercaptopurine or AzathioprineJournal of Clinical Oncology, 2001
- PharmacogeneticsClinical Pharmacokinetics, 2000
- Thiopurine methyltransferase polymorphic tandem repeat: Genotype-phenotype correlation analysisClinical Pharmacology & Therapeutics, 2000
- Mercaptopurine Therapy Intolerance and Heterozygosity at the Thiopurine S-Methyltransferase Gene LocusJNCI Journal of the National Cancer Institute, 1999
- Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemiaBritish Journal of Haematology, 1999
- Prognostic Importance of 6-Mercaptopurine Dose Intensity in Acute Lymphoblastic LeukemiaBlood, 1999
- Genotypic and phenotypic analysis of the polymorphic thiopurine S‐methyltransferase gene (TPMT) in a European populationBritish Journal of Pharmacology, 1998
- Promoter and Intronic Sequences of the Human Thiopurine S-Methyltransferase (TPMT) Gene Isolated from a Human Pacl Genomic LibraryPharmaceutical Research, 1997
- Segregation analysis of human red blood cell thiopurine methyltransferase activityGenetic Epidemiology, 1995